Granules India Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Granules India Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Granules India Ltd.
Rating: 4
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Granules India Ltd. from all sources in a single place.

Granules India Ltd.

18 Sep 2025, 12:00AM

536.65

-1.20%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

We remain positive on Granules' long-term growth and profitability, supported by new product launches across geographies, a focus on backward integration, and rising market share. Entry into the CDMO segment via the Senn acquisition, along with higher-margin oncology filings, is expected to strengthen financials. Moreover, resolution of regulatory issues at the Gagilapur facility could act as a key re-rating catalyst. Hence, we maintain an Accumulate rating on the...

Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 630.0 on 18 Sep, 2025.

Granules India Ltd.

04 Sep 2025

536.65

-1.20%

Company Update

Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Allotment

BSE India

Allotment of Equity Shares of the Company upon exercise of Employee Stock Options

pdf

Granules India Ltd.

22 Aug 2025

536.65

-1.20%

Can Granules India leverage its strong product pipeline to offset recent profit declines?

Economic Times

Granules India's stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the company's product pipeline and business stabilisation. The company anticipates better growth in FY27. Approvals for six products in Europe are awaited. Granules focuses on CNS, ADHD, and oncology products. The Gagillapur facility remediation is progressing well with US FDA.

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

22 Aug 2025

536.65

-1.20%

Modest Q1FY26 growth; facility ramp-up to drive recovery

Buy: Granules India Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.

Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 630.0 on 18 Sep, 2025.

Granules India Ltd.

19 Aug 2025

536.65

-1.20%

Company Update

Granules India Ltd-$ - 532482 - Transcript Of Earning Conference Call For Q1 Of FY26

BSE India

Transcript of Earning Conference Call for Q1 of FY26

pdf

Granules India Ltd.

12 Aug 2025

536.65

-1.20%

Granules India's Q1 FY26 net profit down 1% at 112 cr

Business Line

The total revenue of the Hyderabad-based company increased 3 percent at 1210 crore in the quarter under review as against 1179 crore in the year-ago period